A three-book strategy series
Science creates possibility. Categories decide what becomes usable, fundable, scalable—and durable.
DIAGNOSTICS → BIOPHARMA
01 / THE BOOKS
Each book stands alone. Together they trace how a scientific possibility becomes a category, how that category hardens into an operating system, and where control moves next.
01China and the West in the New Race to Build Diagnostic Categories
A field guide to the moment when strong science must survive translation: workflow, evidence, reimbursement, trust, company form, and ownership. Frontier asks which emerging categories are real—and what it takes to build something the world can carry.
Who turns a discovery into a category?
Find the book02China’s Rise and the New Operating System of Diagnostics
Once a category matures, buyers stop paying for novelty and start paying for continuity: supply, service, software governance, workflow fit, and procurement credibility. Threshold explains why the real product is the operating system that carries the instrument.
Who can carry the category at scale?
Find the book03How Therapeutic Categories Form, Who Controls Them, and How They Are Disrupted
Molecules remain essential, but they are never the full strategic unit. Beyond the Molecule extends the category lens into biopharma, tracing how proof, delivery, infrastructure, clinical practice, economics, and ownership shape what becomes a therapeutic category.
Where does control move after invention?
Explore the framework02 / THE FRAMEWORK
A technology can be excellent and still fail. The series follows the larger system that determines whether invention acquires a usable form, durable legitimacy, and a defensible position.
Form
Discovery must cross the translation relay: evidence, workflow, trust, economics, and ownership.
Carry
Once legitimacy is settled, continuity and integration matter more than novelty alone.
Control
Control moves to infrastructure, evidence, delivery, access, standards, and the ability to renew.
“The science matters. But categories are made—and carried—by systems.”
03 / KEY THEMES
How a scientific possibility becomes a recognized field of action.
Why strong technology stalls at the handoffs between proof, workflow, trust, and economics.
The capabilities around a product that make it deployable, governable, and durable.
How advantage migrates from invention to infrastructure, evidence, access, and renewal.
How two innovation systems increasingly build, validate, scale, and trust differently.
Where to lead, partner, defend, harvest, or exit as a category changes state.
WHO THESE BOOKS ARE FOR
Founders, executives, investors, strategists, operators, technical leaders, commercial teams, and business-unit leaders across diagnostics, life-science tools, healthcare platforms, and biopharma.